Successful treatment with ivabradine in a β-blocker refractory patient with acute decompensated HFrEF

2022 · doi:10.22541/au.166324354.42970949/v1
preprint OA: closed
📄 Open PDF View at publisher

Abstract

Ivabradine is an established treatment for chronic heart failure with reduced ejection fraction (HFrEF) but not for acute heart failure. β-blocker up-titration is often not possible because of its negative inotropic effect (NIE). Ivabradine has no NIE; therefore, it may be preferred over β-blockers in patients with acute decompensated HFrEF.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00